Pharmaceutical Chemistry Research Laboratory II, Department of Pharmaceutical Engineering and Technology, Indian Institute of Technology (BHU), Varanasi, UP, 221005, India.
Institute of Pharmaceutical Research, GLA University, Mathura, UP, 281406, India.
Pharmacol Rep. 2023 Jun;75(3):737-745. doi: 10.1007/s43440-023-00468-2. Epub 2023 Mar 13.
Recently, we have reported an isatin-derived carbohydrazone, 5-chloro-N'-(6-chloro-2-oxoindolin-3-ylidene)-2-hydroxybenzohydrazide (SIH 3) as dual nanomolar FAAH (fatty acid amide hydrolase)-MAGL (monoacylglycerol lipase) inhibitor with good CNS penetration and neuroprotective activity profile. In this study, we further investigated the pharmacological profile of compound SIH 3 in the neuropathic pain model along with acute toxicity and ex vivo studies.
Chronic constrictive injury (CCI) was used to induce neuropathic pain in male Sprague-Dawley rats and the anti-nociceptive activity of the compound SIH 3 was investigated at 25, 50, and 100 mg/kg ip. Subsequently, locomotor activity was measured by rotarod and actophotometer experiments. The acute oral toxicity of the compound was assessed as per the OECD guidelines 423.
Compound SIH 3 showed significant anti-nociceptive activity in the CCI-induced neuropathic pain model without altering the locomotor activity. Furthermore, compound SIH 3 showed an excellent safety profile (up to 2000 mg/kg, po) in the acute oral toxicity study and was also non-hepatotoxic. Further, ex vivo studies revealed that the compound SIH 3 produces a significant antioxidant effect in oxidative stress induced by CCI.
Our findings suggest that the investigated compound SIH 3 has the potential to be developed as an anti-nociceptive agent.
最近,我们报道了一种色胺衍生的缩氨脲,5-氯-N'-(6-氯-2-氧代吲哚啉-3-亚基)-2-羟基苯甲脒(SIH3),作为双重纳摩尔 FAAH(脂肪酸酰胺水解酶)-MAGL(单酰基甘油脂肪酶)抑制剂,具有良好的中枢神经系统渗透和神经保护活性特征。在这项研究中,我们进一步研究了化合物 SIH3 在神经病理性疼痛模型中的药理学特征,以及急性毒性和离体研究。
慢性缩窄性损伤(CCI)用于诱导雄性 Sprague-Dawley 大鼠的神经病理性疼痛,并在 25、50 和 100mg/kg ip 时研究化合物 SIH3 的抗伤害作用。随后,通过转棒和活动光测实验测量运动活动。根据 OECD 指南 423 评估化合物的急性口服毒性。
化合物 SIH3 在 CCI 诱导的神经病理性疼痛模型中表现出显著的镇痛活性,而不改变运动活动。此外,化合物 SIH3 在急性口服毒性研究中表现出极好的安全性(高达 2000mg/kg,po),并且无肝毒性。此外,离体研究表明,该化合物 SIH3 在 CCI 诱导的氧化应激中产生显著的抗氧化作用。
我们的研究结果表明,所研究的化合物 SIH3 有可能被开发为一种镇痛剂。